Compare VRTX & PNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTX | PNC |
|---|---|---|
| Founded | 1989 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Major Banks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 83.9B |
| IPO Year | 2006 | 2010 |
| Metric | VRTX | PNC |
|---|---|---|
| Price | $498.05 | $208.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 20 |
| Target Price | ★ $526.79 | $232.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | ★ 3.30% |
| EPS Growth | ★ 836.54 | 20.74 |
| EPS | 15.32 | ★ 16.59 |
| Revenue | $2,488,652,000.00 | ★ $23,099,000,000.00 |
| Revenue This Year | $10.79 | $16.52 |
| Revenue Next Year | $10.14 | $4.62 |
| P/E Ratio | $29.80 | ★ $12.40 |
| Revenue Growth | ★ 46.20 | 7.16 |
| 52 Week Low | $362.50 | $148.28 |
| 52 Week High | $519.68 | $243.94 |
| Indicator | VRTX | PNC |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 37.60 |
| Support Level | $426.38 | $176.64 |
| Resistance Level | $503.88 | $210.75 |
| Average True Range (ATR) | 15.97 | 6.20 |
| MACD | 0.32 | -2.30 |
| Stochastic Oscillator | 77.49 | 25.70 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
PNC Financial is one of the three super-regional banks in the US, with around $560 billion in total assets at the end of June 30, 2025. Headquartered in Pittsburgh, Pennsylvania, PNC Financial has a coast-to-coast branch network, with a strong presence in the US Midwest and Northeast. It is currently expanding in the Southern and Western regions of the US. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, asset management, and investment banking. PNC derived around 37% of revenue from fee income and 63% from net interest income in 2024.